Opinion
The urgent need for better treatments for Guillain-Barré Syndrome
Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome. That's welcome news.
Sterling Journal-Advocate3d
Guillain Barré-Syndrome and it’s bigger brother CIDP
CIDP is often considered the chronic form of Guillain-Barré Syndrome and, as such, can be more problematic in that it lasts longer, causes more damage and is more difficult to recover from. CIDP ...
Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for ...
Yahoo Finance9d
Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to ...
NorthJersey.com20d
The urgent need for better treatments for Guillain-Barré Syndrome
Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long ...